Synbio International, Inc. (OTC: SYIN) has entered into a Strategic Licensing, Manufacturing, Supply and Revenue Sharing Agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations in the United States and Canada. The agreement covers the flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand, and establishes a framework for evaluating and commercializing additional wellness products over time.
This partnership provides Synbio with immediate access to proprietary products without the time and cost burden of developing formulations from scratch, significantly accelerating the company's path to revenue generation. Under the agreement, MD PHD Wellness will oversee product development, manufacturing, quality assurance, and supply chain management, while Synbio will handle branding, marketing, sales, and distribution. Profits from product sales will be shared between the parties after recovery of approved costs.
Claudio Solitario, CEO of Synbio International, called the agreement a transformative milestone. "Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD's product development and manufacturing expertise with Synbio's commercialization capabilities. It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time," he said.
The nutraceutical market is experiencing rapid global expansion, and Synbio is now positioned to participate through a growing portfolio of scientifically developed products. This move aligns with the company's broader strategy of building a diversified healthcare company that pairs near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies.
MD PHD Wellness was founded by Dr. Robert Lawrence, a physician, scientist, and inventor with two Ph.D.s in Nuclear Physics and Biomedical Engineering. His career spans medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the proprietary formulations licensed to Synbio. His work has included collaborations with leading academic institutions and recognition in Marquis Who's Who.
The agreement advances Synbio's dual-track approach, which the company believes provides multiple avenues for growth while establishing recurring commercial revenue to support continued investment in innovation. Synbio International is focused on clinically validating an AI-driven software that screens for mental health conditions using facial analysis, with plans to launch nutraceutical products sold directly to consumers online in 2026.
This strategic move is significant because it allows Synbio to generate early revenue while its software advances through validation, providing a financial foundation for its long-term AI initiatives. The partnership with MD PHD Wellness not only accelerates Synbio's entry into the nutraceutical market but also positions the company to capitalize on the growing demand for wellness products. By leveraging MD PHD's scientific expertise and manufacturing capabilities, Synbio can focus on building brands and expanding its market presence, creating value for shareholders.
